Journey Medical reports Q1 EPS (18c) vs. (53c) last year

Reports Q1 revenue $13.14M, consensus $12.05M. “The first quarter of 2025 was highly productive, as our in-line dermatology products continue to perform and the launch of Emrosi, our best-in-class oral rosacea treatment, is off to a strong start,” said Claude Maraoui, Journey Medical’s (DERM) Co-Founder, President and Chief Executive Officer. “The Emrosi launch is enjoying high visibility among dermatology prescribers with momentum from our exhibition booth at the American Academy of Dermatology conference in late March, the recent publication of Emrosi’s statistically superior Phase 3 clinical trial results over Oracea and placebo in JAMA Dermatology, and the promotional efforts from our experienced and highly effective dermatology salesforce. Emrosi was also recently incorporated into the National Rosacea Society’s Rosacea Treatment Algorithms, and payer coverage of the product continues to increase.”